Cargando…

Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue

Combretastatin-A4 phosphate (cis -CA-4) is a tubulin-binding agent currently undergoing clinical trials as an anti-tumour drug. We have investigated whether CA-4 functions as a tumour-specific anti-vascular agent using the hyperplastic thyroid as a novel in vivo model of neovascularization. CA-4 eli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Griggs, J, Hesketh, R, Smith, G A, Brindle, K M, Metcalfe, J C, Thomas, G A, Williams, E D
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363811/ https://www.ncbi.nlm.nih.gov/pubmed/11259100 http://dx.doi.org/10.1054/bjoc.2000.1653

Ejemplares similares

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status.
por: Beauregard, D. A., et al.
Publicado: (1998)

Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide
por: Parkins, C S, et al.
Publicado: (2000)

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
por: Grosios, K, et al.
Publicado: (1999)

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate
por: Ibrahim, Mohamed A, et al.
Publicado: (2013)

An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate
por: Williams, L J, et al.
Publicado: (2014)

The interaction with tubulin of a series of stilbenes based on combretastatin A-4.
por: Woods, J. A., et al.
Publicado: (1995)

The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate
por: Holmes, Toby, et al.
Publicado: (2020)

Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues
por: Al-saraireh, Yousef M, et al.
Publicado: (2020)

Magnetic resonance imaging and spectroscopy of combretastatin A(4) prodrug-induced disruption of tumour perfusion and energetic status
Publicado: (1998)

Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models
por: Reipsch, Franziska, et al.
Publicado: (2021)

Expression of topoisomerase III α in normal and neoplastic tissues determined by immunohistochemistry using novel monoclonal antibody
por: Lodge, A J, et al.
Publicado: (2000)

Glycosaminoglycan-synthetic activity of neoplastic and non-neoplastic adipose tissues.
por: Sobue, M., et al.
Publicado: (1980)

Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation
por: Kelly, Patrick M., et al.
Publicado: (2017)

Combretastatin A4 disodium phosphate-induced myocardial injury
por: Tochinai, Ryota, et al.
Publicado: (2016)

The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate
por: Shepherd, Joanna, et al.
Publicado: (2017)

The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4
por: Su, Min, et al.
Publicado: (2016)

Cytotoxicity Studies of Novel Combretastatin and Pterostilbene Derivatives
por: Jakubowska, Joanna, et al.
Publicado: (2014)

Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents
por: Hura, Neha, et al.
Publicado: (2018)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
por: Rustin, G J, et al.
Publicado: (2010)

Synthesis and Cytotoxic Activity of a New Group of Heterocyclic Analogues of the Combretastatins
por: Lipeeva, Alla V., et al.
Publicado: (2014)

Combretastatin A-4 efficiently inhibits angiogenesis and induces neuronal apoptosis in zebrafish
por: Shi, Yun-Wei, et al.
Publicado: (2016)

Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4
por: Lian, Bo, et al.
Publicado: (2021)

Combretastatin A4-camptothecin micelles as combination therapy for effective anticancer activity
por: Assali, Mohyeddin, et al.
Publicado: (2019)

Immunoexpression of Trefoil Factor 1 in Non-Neoplastic and Neoplastic Canine Gastric Tissues
por: Flores, Ana R., et al.
Publicado: (2021)

Detection of codon 12 K- ras mutations in non-neoplastic mucosa from bronchial carina in patients with lung adenocarcinomas
por: Urban, T, et al.
Publicado: (2000)

The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells
por: Dey, Sanchareeka, et al.
Publicado: (2017)

Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101
por: Bao, Xin, et al.
Publicado: (2021)

Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine
por: Jaeckle, K A, et al.
Publicado: (2001)

Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study
por: Gaya, A, et al.
Publicado: (2008)

Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells
por: Cragg, M S, et al.
Publicado: (1999)

Expression of the Class II and III Beta-Tubulin in Neoplastic and Non-Neoplastic Lymphoid Tissues
por: Yusof, Nor Syahida Binti, et al.
Publicado: (2017)

Collagen molecular phenotypic switch between non-neoplastic and neoplastic canine mammary tissues
por: Terajima, Masahiko, et al.
Publicado: (2021)

3D-QSAR Study of Combretastatin A-4 Analogs Based on Molecular Docking
por: Jin, Yinghua, et al.
Publicado: (2011)

Development of Combretastatin A-4 Analogues as Potential Anticancer Agents with Improved Aqueous Solubility
por: Chen, Zhi-Hao, et al.
Publicado: (2023)

Pretreatment with tadalafil attenuates cardiotoxicity induced by combretastatin A4 disodium phosphate in rats
por: Nagashima, Yoshiyasu, et al.
Publicado: (2023)

Docking, Synthesis and Antiproliferative Activity of N-Acylhydrazone Derivatives Designed as Combretastatin A4 Analogues
por: do Amaral, Daniel Nascimento, et al.
Publicado: (2014)

Exploring Diverse-Ring Analogues on Combretastatin A4 (CA-4) Olefin as Microtubule-Targeting Agents
por: Song, Ming-Yu, et al.
Publicado: (2020)

Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors
por: Kumar, Sunil, et al.
Publicado: (2013)

Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications
por: Karatoprak, Gökçe Şeker, et al.
Publicado: (2020)

Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression
por: Dachs, Gabi U, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_012smsb2ijlnpr9l8dg2iht28k